Tag Archives: VBP

Policy Analysis and Guidance: Guangdong Province’s Ninth Batch of National Centralized Drug Procurement Renewal

Leave a reply

Guangdong Province’s Drug Exchange Center has issued a notice regarding the renewal of the ninth batch of national centralized drug procurement for the second procurement year, effective from March 30, 2025, to March 29, 2026. This policy aims to ensure the continuity of drug supply, maintain quality standards, and streamline procurement processes across healthcare institutions.

Key Policy Measures

  1. Viewing Contracted Procurement Volumes
    • Process: Medical institutions and selected enterprises can use CA certificates to log into Guangdong’s tender and procurement subsystem to view contracted procurement volumes. This transparency helps in planning and managing drug distribution efficiently.
  2. Tripartite Contract Signing
    • Procedure: Medical institutions must initiate tripartite contracts through the subsystem, with detailed operational guidance available on the official website. Timely contract completion by all parties is crucial to ensure smooth implementation.
  3. Quality and Supply Assurance
    • Responsibility: Drug manufacturers are held accountable for the quality and timely supply of medications. They must ensure coverage across all participating healthcare institutions in the province, emphasizing reliability in the supply chain.

Policy Orientation and Industry Implications
The renewal initiative underscores Guangdong’s commitment to:

  • Supply Stability: Ensuring uninterrupted drug supply to healthcare facilities.
  • Quality Control: Maintaining high standards for drug quality through clear accountability.
  • Efficiency: Streamlining procurement processes to enhance operational effectiveness.

Conclusion
Guangdong’s approach to centralized drug procurement renewal sets a precedent for regional pharmaceutical management, emphasizing reliability, quality, and efficiency. Stakeholders should adhere to these guidelines to optimize compliance and ensure patient access to essential medications.

Policy Source: https://www.gdmede.com.cn/announcement/announcement/detail?id=1905839740230307840

Policy Analysis and Guidance: Shanghai Announces Second Supply and Incomplete Specification Enterprises for National Drug Procurement

Leave a reply

Shanghai’s Medical Centralized Bidding and Procurement Affairs Management Office has released a notice announcing the determination of second supply and incomplete specification supply enterprises for the tenth batch of national centralized drug procurement. This initiative aims to ensure the stability of drug supply and adaptability to market dynamics, reflecting Shanghai’s commitment to optimizing its centralized procurement system.

Key Policy Highlights

  1. Second Supply and Incomplete Specification Enterprises
    • Purpose: To address market gaps and ensure uninterrupted drug supply.
    • Criteria: Determined based on market share and economic factors.
  2. Market Dynamics Adaptation
    • Flexibility: Provides flexibility in responding to market changes and supply chain disruptions.
  3. Attachment Details
    • Lists: Includes detailed lists of second supply and incomplete specification supply drugs for reference by relevant stakeholders.

Policy Orientation and Industry Implications
The announcement reflects Shanghai’s strategic focus on:

  • Supply Chain Resilience: Ensuring continuous drug availability through diversified supply sources.
  • Market Adaptability: Adapting procurement strategies to meet evolving market conditions.
  • Transparency: Enhancing clarity and accessibility of procurement information for stakeholders.

Conclusion
Shanghai’s approach to determining second supply and incomplete specification enterprises underscores its commitment to maintaining a stable and responsive pharmaceutical market. This policy supports the reliability of the centralized procurement system and ensures patient access to essential medications. Stakeholders should stay informed of these updates to maintain operational efficiency and compliance.-China Health Reform Pulse

Policy Source: https://www.smpaa.cn/xxgk/gggs/2025/03/26/16522.shtml

Policy Analysis and Guidance: China’s Centralized Drug Procurement Information Change Notification

Leave a reply

China’s National Joint Procurement Office has issued a notification regarding the information change of selected drugs in the national centralized drug procurement. This notification allows for changes in drug marketing authorization holders, manufacturers, specifications, packaging, and enterprise names under certain conditions, while maintaining the selected status of the drugs. This move aims to enhance the flexibility and adaptability of the centralized procurement system, ensuring the continuity and stability of drug supply.

Key Policy Highlights

  1. Information Change Allowance
    • Conditions: Under specific conditions, changes in drug-related information are permitted without losing the selected status.
    • Purpose: To maintain the stability of the drug supply chain and adapt to market changes.
  2. Regulatory Compliance
    • Material Review: The change applications are subject to strict verification to ensure compliance with regulatory standards.
  3. Market Implications
    • Supply Stability: Ensures uninterrupted drug supply by allowing necessary information adjustments.
    • Industry Adaptability: Provides flexibility for enterprises to respond to market dynamics while maintaining their position in the procurement system.

Policy Orientation and Industry Implications
The notification reflects China’s strategic focus on:

  • Supply Chain Resilience: Prioritizing the stability and continuity of drug supply.
  • Regulatory Flexibility: Adapting regulatory measures to support industry dynamics and market changes.
  • Market Stability: Ensuring the centralized procurement system remains effective and responsive to industry needs.

Conclusion
China’s approach to allowing information changes in selected drugs under the centralized procurement system demonstrates a balance between regulatory rigor and industry flexibility. This policy supports the stability of the pharmaceutical market and ensures patient access to essential medications. Stakeholders should stay informed of these changes to maintain compliance and operational efficiency.-China Health Reform Pulse

Policy Source: https://www.smpaa.cn/gjsdcg/2025/03/26/16521.shtml